The development and testing of small concentrating PV systems.

Abstract -Spreadsheets have been used to compare some 90 possible small PV concentrator designs that might be suitable for use at remote sites. They have apertures of about 2m 2 , use BP Solar LBG cells, and employ small aperture modules to reduce heat sinking and construction costs. Designs include fixed V-troughs and CPC's, single axis tracked cylindrical lens and mirror systems, and 2-axis tracked spherical-symmetry systems. Performance and volume production costs were estimated. Four promising systems were constructed as prototypes: A -Point-focus Fresnel lenses, 2-axis tracking; Cg = 32x; and 69x with secondaries. B -Line-focus mirror parabolic troughs, 1-axis tracking, Cg = 20x. C -SMTS ('Single-mirror two-stage'), 1-axis tracking, Cg = 30x. F -Multiple line-focus mirror parabolic troughs, E-W 1/day manual tracking, Cg = 6x. The prototypes were tested at Reading, and three for up to a year's field trial at ZSW's test site, Widderstall, in Germany. The best system efficiencies, normalised to 25°C and excluding the end losses of linear systems, were 12.5%, 13.2%, 13.6% and 14.3% for collectors A, B, C, and F, respectively. The collectors were practical and robust, and the performances of collectors B, C and F are only 10% below the estimates in the spreadsheet calculations. The best collectors have estimated production costs between 1.5 and 1.8 US $/Wp, yielding energy costs at a good site (excluding BOS and overheads) of between 5 and 7 cents/kWh (18 and 25 cents/MJ). On the same cost basis a conventional PV array costs 4.3$/Wp, and 18 cents/kWh (65 cents/MJ)

Albert Pierrepoint and the cultural persona of the twentieth-century hangman

Albert Pierrepoint was Britain’s most famous 20th-century hangman. This article utilises diverse sources in order to chart his public representation, or cultural persona, as hangman from his rise to prominence in the mid-1940s to his portrayal in the biopic Pierrepoint(2005). It argues that Pierrepoint exercised agency in shaping this persona through publishing his autobiography and engagement with the media, although there were also representations that he did not influence. In particular, it explores three iterations of his cultural persona – the Professional Hangman, the Reformed Hangman and the Haunted Hangman. Each of these built on and reworked historical antecedents and also communicated wider understandings and contested meanings in relation to capital punishment. As a hangman who remained in the public eye after the death penalty in Britain was abolished, Pierrepoint was an important, authentic link to the practice of execution and a symbolic figure in debates over reintroduction. In the 21st century, he was portrayed as a victim of the ‘secondary trauma’ of the death penalty, which resonated with worldwide campaigns for abolition

Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial

Background Results of small trials indicate that fluoxetine might improve functional outcomes after stroke. The FOCUS trial aimed to provide a precise estimate of these effects. Methods FOCUS was a pragmatic, multicentre, parallel group, double-blind, randomised, placebo-controlled trial done at 103 hospitals in the UK. Patients were eligible if they were aged 18 years or older, had a clinical stroke diagnosis, were enrolled and randomly assigned between 2 days and 15 days after onset, and had focal neurological deficits. Patients were randomly allocated fluoxetine 20 mg or matching placebo orally once daily for 6 months via a web-based system by use of a minimisation algorithm. The primary outcome was functional status, measured with the modified Rankin Scale (mRS), at 6 months. Patients, carers, health-care staff, and the trial team were masked to treatment allocation. Functional status was assessed at 6 months and 12 months after randomisation. Patients were analysed according to their treatment allocation. This trial is registered with the ISRCTN registry, number ISRCTN83290762. Findings Between Sept 10, 2012, and March 31, 2017, 3127 patients were recruited. 1564 patients were allocated fluoxetine and 1563 allocated placebo. mRS data at 6 months were available for 1553 (99·3%) patients in each treatment group. The distribution across mRS categories at 6 months was similar in the fluoxetine and placebo groups (common odds ratio adjusted for minimisation variables 0·951 [95% CI 0·839–1·079]; p=0·439). Patients allocated fluoxetine were less likely than those allocated placebo to develop new depression by 6 months (210 [13·43%] patients vs 269 [17·21%]; difference 3·78% [95% CI 1·26–6·30]; p=0·0033), but they had more bone fractures (45 [2·88%] vs 23 [1·47%]; difference 1·41% [95% CI 0·38–2·43]; p=0·0070). There were no significant differences in any other event at 6 or 12 months. Interpretation Fluoxetine 20 mg given daily for 6 months after acute stroke does not seem to improve functional outcomes. Although the treatment reduced the occurrence of depression, it increased the frequency of bone fractures. These results do not support the routine use of fluoxetine either for the prevention of post-stroke depression or to promote recovery of function. Funding UK Stroke Association and NIHR Health Technology Assessment Programme